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ABSTRACT - Background: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver
burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of
typical neuroleptics are harmful, making atypical neuroleptics an indication. Objectives: To evaluate efficacy
and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD
(agitation). Method: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders
4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg
every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional
Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal
Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated
clinically. Results: There was a 26% reduction in agitation and no cardiovascular side effects in the range from
1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. Conclusion: Risperidone oral solution improved
agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more
acceptable to patients and caregivers.
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Eficácia e segurança de risperidona solução oral na agitação associada a demência em idosos
RESUMO - Fundamentos: Sintomas psicológicos e do comportamento nas demências (BPSD) contribuem para
a sobrecarga dos cuidadores e institucionalização dos idosos. Neurolépticos são prescritos para agitação.
Efeitos colaterais dos típicos são prejudiciais, sendo os atípicos indicáveis. Objetivo: Avaliar eficácia e
tolerabilidade da risperidona solução oral (RSO), dose única diária, em idosos demenciados ambulatoriais
com BPSD (agitação). Método: Pacientes (n=26), 76,35±8,63 anos, critérios do Manual Diagnóstico e Estatístico
de Transtornos Mentais 4.ed. (DSM-IV) para demência. RSO administrada, com dose inicial de 0,25 mg e
incrementos de 0,25 mg toda semana. Foram utilizados mini-mental (MEEM) para estado cognitivo, behavioral
and emotional activities manifested in dementia (BEAM-D) e clinical and global impression (CGI) para BPSD,
extrapyramidal symptom rating scale (ESRS) para sintomas extrapiramidais. Efeitos colaterais cardiovasculares
foram avaliados clinicamente. Resultados: Houve redução de 26% na agitação, sem efeitos colaterais
cardiovasculares, numa faixa de 1,0 a 1,25 mg. Efeitos colaterais foram mais prevalentes acima de 2,5 mg.
Conclusão: Risperidona melhorou agitação com boa tolerabilidade entre 0,5 e 1,25 mg. Dose única diária e
aumentos de 0,25 mg podem ser mais aceitáveis para pacientes e cuidadores.
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Non-cognitive behavioral disorders are prominent
features of dementia1 and often lead to nursing ho-
me placement, besides the patient’s distress, care-
givers’ burden and serious medical complications2-4.
Such disorders have been reported as behavioral and
psychological symptoms of dementia (BPSD), being
present in up to 90% of demented patients stud-
ied1,5,6. The majority of studies published on the sub-
ject deal with case series and/or severely institution-
alized demented patients.
The most conventional pharmacological treat-
ment for these problems is the use of neuroleptics3,7,8.
However, the majority of studies are open label tri-
als with no placebo control, making it difficult to
ascertain the efficacy and side-effect profiles of these
drugs. This is mainly due to difficulties in defining
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agitation, a broad assembly of syndromes that range
from delusions and anxiety manifestations to wan-
dering and so on8,9. Nine double-blind, placebo con-
trolled trials evaluated the use of typical neuroleptics
in dementia. Although haloperidol and thioridazine
have been shown to be superior to placebo in treat-
ing psychotic symptoms in dementia, a considerable
degree of extrapyramidal symptoms have also been
described8. Hence, the efficacy of neuroleptics in
reducing psychotic symptoms in dementia does not
always translate into improvements in daily activi-
ties and functional capacity8.
Atypical neuroleptics have been considered at
least as effective as typical ones in controlling agita-
tion in dementia with the advantage of reduced side
effects and a more favorable EPS profile. Risperidone,
a D2/HT2 blocker, is the most studied atypical antip-
sychotic in BPSD10-13. An open study found risperido-
ne to be safe and effective in treating behavioral sym-
ptoms in 109 demented nursing home residents and
several anecdotal reports have also been published
reconfirming these findings12. To date, only two well-
designed randomized, double-blind, placebo-con-
trolled studies with risperidone for behavioral dis-
turbances in dementia have been published2,14. All
patients included in the above mentioned studies
were institutionalized with severe dementia. Despite
optimal treatment of neuropsychiatric syndromes
and the role of atypical neuroleptics among nursing
home residents being a leading issue in the research
agenda concerning elderly people15, there data do
not allow direct extrapolation to outpatient samples.
Further data are required to ascertain efficacy, dose
range and side effect profile in this population. This
knowledge could prevent unnecessary institutional-
ization, lessen caregiver burden and help rationalize
family and public expenditures.
The present study is the first Brazilian evaluation
of risperidone in dementia, as well as the first trial
administering a daily dose of risperidone oral solu-
tion to an outpatient sample with agitation in de-
mentia. Our objective in this study is to assess the
efficacy and safety of risperidone oral solution in
BPSD in a sample of agitated elderly out patients
with dementia.
METHOD
Twenty-six elderly patients aged 60 years or more, fit-
ting DSM-IV16 criteria for dementia with agitation and/or
psychosis, were treated with increasingly higher doses of
risperidone oral solution. All patients received an initial
dose of 0.25 mg/day followed by increases of 0.25 mg,
up to a maximum of 3.0 mg once daily, according to their
needs. Lorazepan 2 mg was the only medication allowed
for insomnia during the first month of treatment. Biperiden
1mg to 2mg was alloved throughout the study to treat
extrapyramidal symptoms (EPS).
Patients were seen weekly during the first month and
at regular intervals for the proceeding four months to a
total of 9 visits. Two university psychogeriatric units in Rio
de Janeiro and São Paulo – Brazil, took part in the trial,
both approved by the local ethics committee. All patients
and their next of kin signed the informed consent to the
study.
Efficacy was assessed by means of the Behavioral and
Emotional Activities Manifested in Dementia (BEAM-D)17
and Clinical Global Impression (CGI) scales18 , whereas for
cognitive status Mini-Mental State Examination (MMSE)19
were employed. The Extrapyramidal Symptom Rating Scale
(ESRS)20 was used to assess extrapyramidal symptoms
(EPS). Cardiovascular effects where assessed by vital signs
at every visits and electrocadiography (ECG) at baseline
ans last visit.
Data where represented as mean and standard-devia-
tions. Analysis of variance technique was applied to evalu-
ate data variation over time. Pearson’s correlation coeffi-
cient was calculated to measure the correlation grade bet-
ween MMSE and BEAM-D Target Behaviours Scores. Mc-
Nemar’s test was applied to compare the proportion of
patients with EPS at baseline and at final visit. The signifi-
cance level was established at 0.05 and statistical analysis
was performed using the SPSS® statistical package.
RESULTS
26 patients (10 male and 16 female), with mean
age of 76.35±8.63 years, were enrolled on the study.
Alzheimer’s dementia (AD) was present in 17 pa-
tients, vascular dementia (VD) in 5, AD-VD in 6 pa-
tients. Two patients had received typical neuroleptics
prior to the wash out period, and 11 patients were
taking other medications such as digoxin, insulin,
and antihypertensives.
Cognitive impairment was moderate or severe
according to MMSE (Mean of 10.04 and standard-
deviation of 7.09, range = 0 – 25).
Tables 1 and 2 show the mean profile variation
of BEAM-D Target Behaviors and BEAM-D Inferred
State by dose. Comparison between BEAM-D per-
centage scores among doses revealed significant
results for both Target Behaviors and Inferred States
scores (p=0.05 and p<0.001 respectively). For In-
ferred States scores, multiple comparisons among
scores over a dose up to 1.25 mg indicated that the
effective daily dose fell in the range 1.00 mg to 1.25
mg. The difference among doses for Target Beha-
viours ranged between 0.25 mg and 0.50 mg.
Extrapyramidal symptoms were present in 8 pa-
tients during initial screening and in 11 at endpoint.
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Table 3. Patients’ distribution, according to EPS measured by the
ESRS at baseline and last visit.
Baseline Last visit N %
No EPS EPS 5 25.0
No EPS no EPS 8 40.0
EPS EPS 6 30.0
EPS no EPS 1  5.0
Total 20 100
Table 1. Descriptive measures of percentage variation BEAM-D Target Behaviors scores
(compared with visit 1), for each dose.
Dose Mean % SD % Minimum % Maximum % N
0.25 -5.70 24.44 -70.00 62.85 25
0.50 -11.62 19.54 -62.50 28.37 24
0.75 -13.49 18.00 -38.09 18.66 21
1.00 -19.40 16.63 -60.00 0.00 22
1.25 -13.96 15.33 -43.99 9.53 15
1.50 -21.05 19.10 -55.99 11.12 16
1.75 -27.78 17.58 -55.99 0.00 8
2.00 -30.63 11.66 -52.00 -13.63 10
2.25 -40.00 1
Table 2. Descriptive measures of percentage variation of BEAM-D Inferred States scores
(compared with visit 1), for each dose.
Dose Mean % SD % Minimum % Maximum % N
0.25 -5.90 14.14 -44.34 30.00 25
0.50 -9.93 18.75 -38.90 42.29 24
0.75 -15.20 18.55 -50.01 27.27 21
1.00 -19.20 17.84 -47.63 14.28 22
1.25 -23.47 17.23 -41.19 15.38 15
1.50 -26.29 17.47 -50.01 19.24 16
1.75 -35.40 13.27 -50.01 -10.00 8
2.00 -29.69 24.76 -55.01  20.51 10
Table 3 shows the descriptive measures of ESRS
scores for each visit in those patients with positive
scores. There was no significant change in the pro-
portion of patients who presented EPS throughout
the study, since only five patients with no previous
symptoms presented them, all with mild intensity at
endpoint. Eight patients who had not presented EPS
at baseline also had no symptoms at endpoint,
whereas six who had shown EPS at baseline remained
unchanged and one patient improved by endpoint
(p=0.2188) (Table 4). No cardiovascular or clinical
side effects were observed with dose increase dur-
ing the four months of the trial (Table 5).
Nine patients dropped out of the study (34.6%):
2 due to insufficient response, 4 owing to side ef-
fects and 3 for loss of follow up and consent with-
drawal. All but one patient who had dropped out
were considered severe/marked in CGI for agitation.
All dropouts due to side effects had EPS.
DISCUSSION
Risperidone oral solution was effective in control-
ling BPSD, demonstrated by a mean reduction of 26%
in the BEAM-D score in this sample of demented eld-
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erly outpatients after a four month period. A recent
meta-analysis of randomized, double-blind control-
led trials involving neuroleptics in behavioral disor-
ders associated with dementia showed therapeutic
effect to be only 26% (neuroleptic minus placebo)
and showed no difference between high and low
potency profiles of these drugs9. Two further stud-
ies, the first being a randomized, placebo controlled,
double-blind design of risperidone for agitation in
dementia, have produced similar results, albeit in
severely demented institutionalized samples2,14. De
Deyn found only 11% more patients in the rispe-
ridone group and 8% in the haloperidol group to
have improved, compared to the placebo control
group14,15.
Clinicians would prefer treatment data on spe-
cific target behaviors and disturbances such as de-
lusions, aggression, anxiety, and mood disturbances
given that this is how they select drugs in clinical
practice15. Symptoms of aggression, restlessness, de-
lusions, hallucinations and inappropriate sexual be-
havior seem to show a better response to medica-
tion whereas wandering and utterances respond po-
orly to any kind of treatment21,22.
Patients with cognitive impairment are more pro-
ne to aggressive behavior and wandering than those
with milder impairment, who show more verbal agi-
tated behaviors. However, this is observed mainly in
institutions23. A recent nine year prospective study
on the relationship between cognition and BPSD in
a community sample of demented patients failed to
show such tendencies. BPSD symptoms may appear
in the beginning of the disease in its interim or final
stages and can last for a period or become chronic,
thus displaying no organization according to cogni-
tive status. This study does not support the view that
behavioral and psychiatric changes occur predomi-
nantly at any one stage of the illness24.
Most published data on agitation in the elderly,
especially in dementia, does not specify which tar-
get symptoms have been evaluated. This often leads
to unclear conclusions concerning the efficacy of the
medication studied. BEAM-D is an effective tool for
psychopathological description of the symptoms and
their intensity, although the present study could be
criticized for having used an instrument not com-
monly applied in similar trials, thus making it diffi-
cult to compare our results with those found in other
studies. This was an outpatient sample of moderately
and severely demented elderly. Taking this into con-
sideration, it is interesting to note that the progres-
sion of cognitive decline does not necessarily correla-
te with a worsening of agitation when treatment is
implemented. This may be important in preventing
unnecessary institutionalization of patients with de-
mentia, given that better control of insomnia, ag-
gressiveness and psychosis may reduce caregiver
burden to a more manageable level.
The likely duration of episodes of a given behav-
ior is also relevant in that the length of treatment
may be determined. Episodes of physical aggression
lasted less than 10 months in 25% of AD patients
from a prospective study of a community sample24.
Therefore, our trial has covered a time period dur-
ing which no remission would be expected in the
Table 5. Distribution of patients according to ECG results at first
and last visits.
First ECG Last ECG N %
Normal Normal 7 87.5
Abnormal 1 12.5
Total 8 100
Abnormal Normal 2 15.4
Abnormal 11 84.6
Total 13 100
Table 4. Descriptive measures of ESRS scores in each visit, for patients with non-null scores.
Mean SD Minimum Maximum N# N&
Visit 1 6.25 4.87 2.78 13.89 8 26
Visit 5 4.37 2.18 2.78  8.33 7 22
Visit 7 4.72 3.71 2.78 13.89 10 21
Visit 8 6.75 4.49 2.78 13.89 7 19
Final Visit 8.84 5.80 2.78 16.67 11 20
#, number of patients with non-null scores;&, number of patients with non-missing scores.
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absence of treatment for most of the patients stud-
ied. Nevertheless, optimal duration of treatment has
yet to be determined through appropriately designed
controlled-studies.
The safety profile of risperidone oral solution in
our study was good in respect of the emergence of
EPS symptoms and cardiovascular side effects. Since
only five patients without previous EPS showed mild
EPS at endpoint, and eight presenting no such symp-
toms at baseline remained so at endpoint, we can
regard risperidone as having a favorable profile con-
cerning EPS. This data is also in agreement with that
of other open label studies, a recently published ret-
rospective study in outpatients, as well as the double-
blind risperidone trial2,3,25. De Deyn et al.15 compared
risperidone and haloperidol with 0.25 mg as a start-
ing dose, followed by 0.25 mg increments every four
days and found riperidone to be as effective as ha-
loperidol. Risperidone had a better side effect pro-
file than haloperidol, compared with placebo.
Our trial also used a once a day ingestion sched-
ule. This regimen was safe, acceptable to caregivers
and effective in controlling the target symptoms.
That said, the oral solution formulation may offer
the additional advantage of lowering the dose re-
quired to control agitation, while allowing a 0.25
mg increment schedule, should lower strength
risperidone tablets not be available, thus reducing
EPS side effects.
Dropout rates are within the range observed in
studies of a similar nature. Katz2 and DeDeyn15 had a
30% and 35.2% dropout rate, respectively, while me-
ta-analytic studies showed a 4% difference in drop-
outs between placebo and active drug9. Since most
of our dropouts were because of side effects com-
bined with insufficient response, mainly in a series
of more severely agitated patients, the present data
are in line with the current literature.
There are several limitations to our study that
should be taken into account when considering our
data. We conducted an open label trial including
both AD and VD patients. Even though there was a
washout period for previous neuroleptics and other
medications which controlled agitation, it could be
argued that side effects and the response profile of
patients may have differed from that expected if
homogenized group of patients with no previous
medication were tested with risperidone. Many pa-
tients also had a series of concurrent diseases such
as hypertension and diabetes, albeit under control
at the time of inclusion. However, excluding patients
for these medical reasons would be tantamount to
excluding the “real life” circumstances that often
intervene in clinical decisions. Further studies could
be carried out with a more homogeneous sample of
“pure” AD or VD patients. The use of BEAM-D could
also be a focus of criticism as it has not commonly
been used in similar studies, thus making generali-
zation more difficult. On the other hand, BEAM-D
has a complete set of definitions for each severity
state and described behaviour, making it a suitable
tool for defining and measuring intensity in a strai-
ghtforward manner.
A considerable number of patients showed EPS
at baseline. Biperiden 1mg to 2 mg was the only
antiparkinsonian medication used to lessen EPS,
when needed. Of the seven patients who received
this drug, all presented EPS at baseline. We also
found it valuable to learn what might be the out-
come of these patients with risperidone, although it
can also be argued that the effect of risperidone
alone on EPS in this sample could not be ascertained.
CONCLUSION
Risperidone was safe and effective in controlling
agitation in dementia with a minimum of side ef-
fects regarding cardiovascular and extrapyramidal
symptoms. The dose that showed a significant dif-
ference in controlling these symptoms varied from
1.00 mg to 1.25 mg once daily, providing a reduc-
tion of 26% in agitation and related states in an
outpatient sample.
These results are akin to those of other open la-
bel studies with risperidone in dementia, except that
ours is the first to use an oral solution formulation.
Since only two double-blind placebo controlled
studies with risperidone for BPSD in institutionalized
demented elderly have been published so far, there
is still a need to study community and outpatient
samples to ascertain the best treatment schedule,
with the aim of maximizing efficacy with the least
side effects possible.
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